×

Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016

PALO ALTO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco.

Eiger BioPharmaceuticals management is scheduled to present on Wednesday, September 7 at 1:30 p.m. Pacific time, with one-on-one meetings held throughout the conference.

The presentation will be webcast live and available for replay in the Investor Relations section of Eiger BioPharmaceuticals website at www.eigerbio.com or on the Gateway Conference website at www.gateway-conference.com/presenters.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email gateway@liolios.com.

About the Gateway Conference
The 5th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.

About Eiger BioPharmaceuticals
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The Company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contact:
Jim Shaffer
jshaffer@eigerbio.com
(919) 345-4256

Source:Eiger BioPharmaceuticals, Inc.